Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pancreatic cancer heterogeneity and response to Mek inhibition.
Pedersen K, Bilal F, Bernadó Morales C, Salcedo MT, Macarulla T, Massó-Vallés D, Mohan V, Vivancos A, Carreras MJ, Serres X, Abu-Suboh M, Balsells J, Allende E, Sagi I, Soucek L, Tabernero J, Arribas J. Pedersen K, et al. Among authors: soucek l. Oncogene. 2017 Oct 5;36(40):5639-5647. doi: 10.1038/onc.2017.174. Epub 2017 Jun 5. Oncogene. 2017. PMID: 28581516
Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis.
Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, Redondo-Campos S, Folch G, Gonzàlez-Juncà A, Sodir NM, Massó-Vallés D, Beaulieu ME, Swigart LB, Mc Gee MM, Somma MP, Nasi S, Seoane J, Evan GI, Soucek L. Annibali D, et al. Among authors: soucek l. Nat Commun. 2014 Aug 18;5:4632. doi: 10.1038/ncomms5632. Nat Commun. 2014. PMID: 25130259 Free PMC article.
Ibrutinib repurposing: from B-cell malignancies to solid tumors.
Massó-Vallés D, Jauset T, Soucek L. Massó-Vallés D, et al. Among authors: soucek l. Oncoscience. 2016 Jun 10;3(5-6):147-8. doi: 10.18632/oncoscience.310. eCollection 2016. Oncoscience. 2016. PMID: 27489860 Free PMC article. No abstract available.
Interrogating open issues in cancer precision medicine with patient-derived xenografts.
Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Byrne AT, et al. Among authors: soucek l. Nat Rev Cancer. 2017 Apr;17(4):254-268. doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20. Nat Rev Cancer. 2017. PMID: 28104906 Free article. Review.
BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC.
Jauset T, Massó-Vallés D, Martínez-Martín S, Beaulieu ME, Foradada L, Fiorentino FP, Yokota J, Haendler B, Siegel S, Whitfield JR, Soucek L. Jauset T, et al. Among authors: soucek l. Oncotarget. 2018 Apr 10;9(27):18734-18746. doi: 10.18632/oncotarget.24648. eCollection 2018 Apr 10. Oncotarget. 2018. PMID: 29721157 Free PMC article.
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.
Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano Del Pozo E, Fiore C, Foradada L, Cano VC, Sánchez-Hervás M, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martín G, Letourneau D, Montagne M, Morcillo Alonso MÁ, Whitfield JR, Lavigne P, Soucek L. Beaulieu ME, et al. Among authors: soucek l. Sci Transl Med. 2019 Mar 20;11(484):eaar5012. doi: 10.1126/scitranslmed.aar5012. Sci Transl Med. 2019. PMID: 30894502 Free PMC article.
MYC, MYCL, and MYCN as therapeutic targets in lung cancer.
Massó-Vallés D, Beaulieu ME, Soucek L. Massó-Vallés D, et al. Among authors: soucek l. Expert Opin Ther Targets. 2020 Feb;24(2):101-114. doi: 10.1080/14728222.2020.1723548. Epub 2020 Feb 13. Expert Opin Ther Targets. 2020. PMID: 32003251 Review.
74 results